DGAP-Adhoc: 4SC AG announces subscription price for new shares from current capital increase


4SC AG  / Key word(s): Capital Increase/Financing

02.07.2015 22:14

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc release pursuant to Section 15 of the German Securities Trading Act
(Wertpapierhandelsgesetz, WpHG)

NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN THE UNITED STATES,
AUSTRALIA, CANADA OR JAPAN.

4SC AG announces subscription price for new shares from current capital
increase

  - Subscription price set at EUR 4.00 per new share

  - Subscription period scheduled to end on 6 July 2015 at 24:00 hrs.
    midnight (CEST)

Planegg-Martinsried, Germany, 2 July 2015 - The Management Board of 4SC AG
(Frankfurt, Prime Standard: ISIN DE000A14KL72, VSC) today resolved, with
the approval of the Supervisory Board, the subscription price for the
ongoing cash capital increase at EUR 4.00 per new share. As announced in
the Company's ad hoc release on 22 June 2015, the subscription price was
determined taking into account the volume-weighted average price (VWAP) of
4SC AG in the XETRA electronic trading system on the Frankfurt Stock
Exchange from the beginning of the subscription period on 23 June 2015
until close of trading on 2 July 2015, less a discount. The VWAP of the 4SC
share in the relevant period was EUR 4.53, hence the granted discount
amounts to 11.7%. The ongoing subscription period for the new shares is
scheduled to end at 24:00 hrs. midnight (CEST) on 6 July 2015. Any new
shares not subscribed for will be offered to selected institutional
investors as private placements.

4SC AG intends to issue up to approximately 8.2 million new shares by cash
contributions for the further development of its existing research and
development programmes, in particular for the financing of a planned
clinical Phase II trial with its lead anti-cancer agent resminostat in the
tumour indication of cutaneous T-cell lymphoma (CTCL).

In addition, the Company plans to issue up to approximately 2.0 million new
shares (Consideration Shares) for the same issue price of EUR 4.00 as part
of a capital increase against contributions in kind in order to swap a
substantial portion of an existing loan from major shareholder Santo
Holding (Deutschland) GmbH into equity. Overall, through both capital
measures, 4SC AG intends to increase its share capital from EUR
10,216,646.00, composed of 10,216,646 no-par value bearer shares, to up to
EUR 20,433,292.00, composed of up to 20,433,292 shares, while partially
utilising authorised capital.

Further details on the capital increase can be found in 4SC's ad hoc
release dated 22 June 2015 and on the websites www.4sc.de and
www.capital.4sc.de, where also the rights offering and the securities
prospectus are available.


---------------------------------------------------------------------------

Information and Explaination of the Issuer to this News:

Use of proceeds: 

4SC AG intends to use the proceeds from the cash capital increase primarily
for the further clinical development of its epigenetic anti-cancer compound
resminostat in the indication of cutaneous T-cell lymphoma (CTCL). In
particular, the Company plans to finance a clinical Phase II trial in this
haematological cancer indication scheduled to begin in early 2016. If
successful, the trial data could be the basis for an application for
conditional approval on the European market. The Company intends to secure
its overall financing until the results of the CTCL study are expected in
the second half of 2018. Furthermore, the proceeds will serve to further
accelerate preparations for clinical Phase II trials with the anti-cancer
compound 4SC-202, the initiation of partnerships for the further clinical
development of the anti-cancer compound 4SC-205 and negotiations with
potential partners concerning all of the Company's compounds.


About 4SC

The Group managed by 4SC AG (ISIN DE000A14KL72) discovers and develops
targeted, small-molecule drugs for treating diseases with high unmet
medical needs in various cancer and autoimmune indications. These drugs are
intended to provide innovative treatment options that are more tolerable
and efficacious than existing therapies, and provide a better quality of
life. The Company's pipeline comprises promising products that are in
various stages of clinical development. 4SC's aim is to generate future
growth and enhance its enterprise value by entering into partnerships with
pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount
of 68 employees (58 FTEs) at 31 March 2015. 4SC AG has been listed on the
Prime Standard of the Frankfurt Stock Exchange since December 2005.


Legal note

These materials do not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities in the United States,
Germany or any other jurisdiction. The shares (the 'Shares') of 4SC AG (the
'Company') may not be offered or sold in the United States absent
registration or an exemption from registration under the U.S. Securities
Act of 1933, as amended. The Company does not intend to register any
portion of the offering in the United States or to conduct a public
offering of Shares in the Company in the United States.

This publication constitutes neither an offer to sell nor a solicitation to
buy securities. The offer will be made solely by means of, and on the basis
of, a securities prospectus. The prospectus is available for free at 4SC
AG, Am Klopferspitz 19a, 82152 Planegg-Martinsried, Germany, and on the
websites of 4SC AG at www.4SC.de and www.capital.4SC.de.


Cautionary statement regarding forward-looking statements

This press release contains certain forward-looking statements. Any
forward-looking statement applies only on the date of this press release.
By their nature, forward-looking statements are subject to a number of
known and unknown risks and uncertainties that may or may not occur in the
future and as a result of which the actual results and performance may
differ substantially from the expected future results or performance
expressed or implied in the forward looking statements. No warranties or
representations are made as to the accuracy, achievement or reasonableness
of such statements, estimates or projections, and 4SC AG has no obligation
to update any such information or to correct any inaccuracies herein or
omission herefrom which may become apparent.


For more information please visit www.4sc.com or contact:

4SC AG
Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at)4sc.com, Tel.: +49-89-7007-6366

MC Services
Katja Arnold, Michelle Kremer
katja.arnold(at)mc-services.eu, Tel.: +49-89-2102-2840

02.07.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      4SC AG
              Am Klopferspitz 19a
              82152 Martinsried
              Germany
Phone:        +49 (0)89 7007 63-0
Fax:          +49 (0)89 7007 63-29
E-mail:       public@4sc.com
Internet:     www.4sc.de
ISIN:         DE000A14KL72
WKN:          A14KL7
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated
              Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart,
              Tradegate Exchange
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------